BriaCell received FDA IND clearance for Bria-PROS+, launching the next step for its personalized off-the-shelf, cell-based immunotherapy platform in prostate cancer. The company plans to initiate a Phase I/IIa study to evaluate safety, dosing, and early signals of activity. Bria-PROS+ is described as an immunotherapy designed to be both personalized and broadly usable through an off-the-shelf format—an approach intended to reduce manufacturing delays that can constrain cell therapy access in oncology. The IND clearance extends BriaCell’s clinical momentum as the company seeks to bring its cell-based product pipeline into human testing in a high-incidence solid tumor indication.